The 36-month beta value for TSHA is also noteworthy at 0.89. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TSHA is 165.06M, and at present, short sellers hold a 14.02% of that float. The average trading volume of TSHA on May 06, 2025 was 2.25M shares.
TSHA) stock’s latest price update
Taysha Gene Therapies Inc (NASDAQ: TSHA)’s stock price has dropped by -4.65 in relation to previous closing price of 2.58. Nevertheless, the company has seen a gain of 36.67% in its stock price over the last five trading days. globenewswire.com reported 2025-05-02 that DALLAS, May 02, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2025, the Compensation Committee of Taysha’s Board of Directors granted one new employee an option to purchase 45,000 shares of the Company’s common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
TSHA’s Market Performance
TSHA’s stock has risen by 36.67% in the past week, with a monthly rise of 95.24% and a quarterly rise of 60.78%. The volatility ratio for the week is 12.30% while the volatility levels for the last 30 days are 12.16% for Taysha Gene Therapies Inc The simple moving average for the past 20 days is 50.94% for TSHA’s stock, with a 28.19% simple moving average for the past 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with BMO Capital Markets repeating the rating for TSHA by listing it as a “Outperform.” The predicted price for TSHA in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on June 27, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $9. The rating they have provided for TSHA stocks is “Overweight” according to the report published on April 09th, 2024.
Jefferies gave a rating of “Hold” to TSHA, setting the target price at $1.50 in the report published on February 01st of the previous year.
TSHA Trading at 50.05% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.06% of loss for the given period.
Volatility was left at 12.16%, however, over the last 30 days, the volatility rate increased by 12.30%, as shares surge +101.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.80% upper at present.
During the last 5 trading sessions, TSHA rose by +36.67%, which changed the moving average for the period of 200-days by +7.42% in comparison to the 20-day moving average, which settled at $1.63. In addition, Taysha Gene Therapies Inc saw 42.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 1,333,333 shares at the price of $2.25 back on Jun 27 ’24. After this action, Manning Paul B now owns 1,333,333 shares of Taysha Gene Therapies Inc, valued at $2,999,999 using the latest closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -10.98 for the present operating margin
- 1.0 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -10.72. The total capital return value is set at -0.68. Equity return is now at value -121.94, with -32.87 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -1.29. The debt to equity ratio resting at 0.88. The interest coverage ratio of the stock is -896.66.
Currently, EBITDA for the company is -87.95 million with net debt to EBITDA at 0.86. When we switch over and look at the enterprise to sales, we see a ratio of 51.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.41.
Conclusion
In summary, Taysha Gene Therapies Inc (TSHA) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
